C4 Therapeutics (CCCC) Gains from Investment Securities (2019 - 2022)

C4 Therapeutics' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $185227.0 for Q1 2022.

• In Q1 2022, Gains from Investment Securities fell 96.89% year-over-year to $185227.0; the TTM figure through Dec 2022 stood at $20.1 million (changed N/A YoY), while the FY2022 annual figure was $44.1 million, up 636.48% from the prior year.
• Gains from Investment Securities was $185227.0 for Q1 2022 at C4 Therapeutics, down from $20.1 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $20.1 million in Q4 2021 to a low of $185227.0 in Q1 2022.
• Historically, Gains from Investment Securities has averaged $4.7 million across 4 years, with a median of $2.4 million in 2019.
• The sharpest annual moves came in 2021 and 2022: Gains from Investment Securities jumped 694.12% in 2021, then plunged 96.89% in 2022.
• A 4-year view of Gains from Investment Securities shows it stood at $2.3 million in 2019, then advanced by 9.7% to $2.5 million in 2020, then surged by 694.12% to $20.1 million in 2021, then plunged by 99.08% to $185227.0 in 2022.
• The last three Gains from Investment Securities figures came in at $185227.0 (Q1 2022), $20.1 million (Q4 2021), and $1.6 million (Q3 2021), per Business Quant data.